{
  "docId": "019de075-da5f-7126-b0c8-5ad6b3fad507",
  "docSlug": "2367b4018d9bb2d1e01ea441f685753d",
  "documentTitle": "Neumora Therapeutics | IPO Presentation Deck | 32 slides",
  "authorId": "neumora-therapeutics",
  "authorName": "Neumora Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 21,
  "pageCount": 32,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a biological pathway diagram to illustrate the mechanism of action (PAM) and the pathology of schizophrenia.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-da5f-7126-b0c8-5ad6b3fad507/21",
  "deckHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507",
  "deckJsonHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507.json",
  "deckAnchorHref": "/decks/019de075-da5f-7126-b0c8-5ad6b3fad507#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.12,
        "x": 0.41,
        "y": 0.17
      },
      "kind": "callout",
      "text": "Strong Biological Rationale: Glutamate is the major excitatory neurotransmitter in the brain and dysregulation is believed to be a key driver of schizophrenia",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41a77616-73ee-4f03-979f-649a995e9ec1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.42,
        "x": 0.55,
        "y": 0.17
      },
      "kind": "image",
      "text": "Biological pathway diagram showing NMDA receptor, PAM interaction, and downstream effects on GABA and Dopamine pathways.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16e283b4-9a3a-4d1e-97c2-e1ddf38b0177",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.38,
        "x": 0.03,
        "y": 0.41
      },
      "kind": "list",
      "text": "Indication: Schizophrenia",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00f7b137-f87f-4e03-bba6-544876c79622",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.38,
        "x": 0.03,
        "y": 0.18
      },
      "kind": "list",
      "text": "Pharmacology: NMDA receptor hypofunction is a leading hypothesis for the cause of schizophrenia. NMDA positive allosteric modulators (PAMs) can selectively enhance physiological NMDAR function, decrease network hypersynchrony and improve symptoms.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c887919-1115-42af-a20f-a3cf1182b767",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.38,
        "x": 0.03,
        "y": 0.67
      },
      "kind": "list",
      "text": "Drug Profile: Oral, once-daily",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72004eef-3500-458b-aa29-152c075f00c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.38,
        "x": 0.03,
        "y": 0.58
      },
      "kind": "list",
      "text": "Status: Undergoing IND-enabling activities",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9fd7ff7-54ff-4f7d-ab8f-55fe77835ad1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.38,
        "x": 0.03,
        "y": 0.76
      },
      "kind": "list",
      "text": "Strong IP Protection: Expect exclusivity through 2044+, based on composition of matter protection plus potential for patent term extension",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9053349-bbcb-4413-9268-917232742f53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.38,
        "x": 0.03,
        "y": 0.49
      },
      "kind": "list",
      "text": "Epidemiology: Estimated ~3 million patients in the U.S. with schizophrenia",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f403fc37-e5cf-4811-bf7c-8a0576500291",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.8,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "NMRA-NMDA: Novel Approach for the Treatment of Schizophrenia",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f91affe-10f7-4734-99f9-190ca4a17ac4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}